Lepu Biopharma Co. Ltd. Class H (HK:2157) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Lepu Biopharma Co., Ltd. has announced that its drug candidate MRG003, aimed at treating recurrent or metastatic nasopharyngeal cancer, has been accepted for review and granted priority by China’s NMPA. This marks a significant milestone for the company, potentially accelerating MRG003’s commercialization and bolstering the company’s competitiveness in the oncology market. However, the company warns that there is no certainty of MRG003’s successful development or market success.
For further insights into HK:2157 stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue